Trial
NCT05997277
Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Beth Israel Deaconess Medical Center
Collaborators
Bristol-Myers Squibb
Condition
Hidradenitis Suppurativa
Intervention
Deucravacitinib
Why stopped
Funding withdrawn by sponsor due to funding priorities, study cannot continue without funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-29